当前位置: 首页 >> 检索结果
341. Intravenous neridronate in the treatment of acute painful knee osteoarthritis: a randomized controlled study.
作者: Massimo Varenna.;Francesca Zucchi.;Simonetta Failoni.;Andrea Becciolini.;Massimo Berruto.
来源: Rheumatology (Oxford). 2015年54卷10期1826-32页
The aim of this randomized, double-blind, placebo-controlled study was to assess the efficacy of i.v. neridronate in controlling pain in patients with acute painful knee OA.
342. Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy.
作者: Divi Cornec.;Valérie Devauchelle-Pensec.;Xavier Mariette.;Sandrine Jousse-Joulin.;Jean-Marie Berthelot.;Aleth Perdriger.;Xavier Puéchal.;Véronique Le Guern.;Jean Sibilia.;Jacques-Eric Gottenberg.;Laurent Chiche.;Eric Hachulla.;Pierre Yves Hatron.;Vincent Goeb.;Gilles Hayem.;Jacques Morel.;Charles Zarnitsky.;Jean Jacques Dubost.;Raphaèle Seror.;Jacques-Olivier Pers.;Petra M Meiners.;Arjan Vissink.;Hendrika Bootsma.;Emmanuel Nowak.;Alain Saraux.
来源: Rheumatology (Oxford). 2015年54卷9期1699-708页
To determine which outcome measures detected rituximab efficacy in the Tolerance and Efficacy of Rituximab in Sjögren's Disease (TEARS) trial and to create a composite endpoint for future trials in primary SS (pSS).
343. Maintenance of improvement in spinal mobility, physical function and quality of life in patients with ankylosing spondylitis after 5 years in a clinical trial of adalimumab.
作者: Désirée van der Heijde.;Maxime Breban.;Dale Halter.;Gino DiVittorio.;Johan Bratt.;Fabrizio Cantini.;Sonja Kary.;Aileen L Pangan.;Hartmut Kupper.;Suchitrita S Rathmann.;Joachim Sieper.;Phillip J Mease.
来源: Rheumatology (Oxford). 2015年54卷7期1210-9页
Chronic pain and progressive loss of physical function with AS may adversely affect health-related quality of life (HRQoL). The objective of this study was to assess the 5-year data regarding spinal mobility, physical function and HRQoL in patients with AS who participated in the Adalimumab Trial Evaluating Long-term Efficacy and Safety for AS (ATLAS) study.
344. A randomized controlled trial for improving patient self-assessment of synovitis in rheumatoid arthritis with education by ultrasonography: the RAEUS Study.
作者: Peter P Cheung.;Manjari Lahiri.;Gim Gee Teng.;Anita Y N Lim.;Tang Ching Lau.;Aisha Lateef.;Anselm Mak.;Laure Gossec.;Lyn March.
来源: Rheumatology (Oxford). 2015年54卷7期1161-9页
Patients can potentially monitor disease activity of RA through self-assessed swollen joints (clinical synovitis), but reliability is poor. The objective is to evaluate the use of education by US feedback on the ability of patients to assess for clinical synovitis in RA.
345. Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids.
作者: Fowzia Ibrahim.;Ernest Choy.;Patrick Gordon.;Caroline J Doré.;Alan Hakim.;George Kitas.;David Isenberg.;Bridget Griffiths.;Bryan Lecky.;Kuntal Chakravarty.;John Winer.;Katalin Danko.;Robert G Cooper.;Beverley White-Alao.;David L Scott.
来源: Rheumatology (Oxford). 2015年54卷6期1050-5页
Ciclosporin and MTX are used in idiopathic inflammatory myopathies (DM and PM) when patients incompletely respond to glucocorticoids. Their effectiveness is unproved in randomized controlled trials (RCTs). We evaluated their benefits in a placebo-controlled factorial RCT.
346. Tight control of rheumatoid arthritis in a resource-constrained setting: a randomized controlled study comparing the clinical disease activity index and simplified disease activity index.
作者: Bridget Hodkinson.;Eustatius Musenge.;Mohammed Tikly.
来源: Rheumatology (Oxford). 2015年54卷6期1033-8页
The aim of this study was to explore the clinical utility of the clinical disease activity index (CDAI). We compared the disease control with protocolized treatment adjustment following a tight control strategy utilizing either the simplified disease activity index (SDAI) or the CDAI.
347. Joint protection and hand exercises for hand osteoarthritis: an economic evaluation comparing methods for the analysis of factorial trials.
作者: Raymond Oppong.;Sue Jowett.;Elaine Nicholls.;David G T Whitehurst.;Susan Hill.;Alison Hammond.;Elaine M Hay.;Krysia Dziedzic.
来源: Rheumatology (Oxford). 2015年54卷5期876-83页
Evidence regarding the cost-effectiveness of joint protection and hand exercises for the management of hand OA is not well established. The primary aim of this study is to assess the cost-effectiveness (cost-utility) of these management options. In addition, given the absence of consensus regarding the conduct of economic evaluation alongside factorial trials, we compare different analytical methodologies.
348. Economic evaluation of a brief education, self-management and upper limb exercise training in people with rheumatoid arthritis (EXTRA) programme: a trial-based analysis.
作者: Victoria L Manning.;Billingsley Kaambwa.;Julie Ratcliffe.;David L Scott.;Ernest Choy.;Michael V Hurley.;Lindsay M Bearne.
来源: Rheumatology (Oxford). 2015年54卷2期302-9页
The aim of this study was to conduct a cost-utility analysis of the Education, Self-management and Upper Limb Exercise Training in People with RA (EXTRA) programme compared with usual care.
349. Prevention of new osteitis on magnetic resonance imaging in patients with early axial spondyloarthritis during 3 years of continuous treatment with etanercept: data of the ESTHER trial.
作者: In-Ho Song.;Kay-Geert Hermann.;Hildrun Haibel.;Christian E Althoff.;Denis Poddubnyy.;Joachim Listing.;Anja Weiß.;Ekkehard Lange.;Bruce Freundlich.;Martin Rudwaleit.;Joachim Sieper.
来源: Rheumatology (Oxford). 2015年54卷2期257-61页
The aim of this study was to assess the degree of fluctuation of osteitis on MRI during long-term treatment with etanercept (ETN) in patients with early axial SpA (axSpA) with active inflammation (osteitis) on whole-body MRI in the spine and/or the SI joints at baseline.
350. Is colour duplex sonography-guided temporal artery biopsy useful in the diagnosis of giant cell arteritis? A randomized study.
作者: Giuseppe Germanò.;Francesco Muratore.;Luca Cimino.;Alberto Lo Gullo.;Niccolò Possemato.;Pierluigi Macchioni.;Alberto Cavazza.;Nicolò Pipitone.;Luigi Boiardi.;Carlo Salvarani.
来源: Rheumatology (Oxford). 2015年54卷3期400-4页
The aim of this study was to assess the usefulness of colour duplex sonography (CDS)-guided temporal artery biopsy (TAB) for the diagnosis of GCA in patients with suspected GCA.
351. Does ultrasound-scored synovitis depend on the pharmacokinetics of subcutaneous anti-TNF agents in patients with rheumatoid arthritis?
作者: Esperanza Naredo.;Michelle Hinojosa.;Lara Valor.;Diana Hernández-Flórez.;Carmen Mata-Martínez.;Belén Serrano-Benavente.;Tamara Del Río.;Natalia Bello.;María Montoro.;Juan Carlos Nieto-González.;Carlos M González.;Francisco Javier López-Longo.;Indalecio Monteagudo.;Luis Carreño.
来源: Rheumatology (Oxford). 2014年53卷11期2088-94页
The aim of this study was to investigate the influence of the pharmacokinetics of s.c. anti-TNF agents on the grade of US-detected synovitis in RA patients.
352. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
作者: Roy Fleischmann.;Andrew S Koenig.;Annette Szumski.;Henk W Nab.;Lisa Marshall.;Eustratios Bananis.
来源: Rheumatology (Oxford). 2014年53卷11期1984-93页
The aims of this study were to investigate the short-term benefit of etanercept (ETN) + MTX vs conventional synthetic DMARDs (csDMARDs; HCQ, LEF or SSZ) + MTX in subjects with established RA. The effect of disease duration (≤2 years vs >2 years) and severity (moderate vs severe) on treatment outcomes was also assessed. Methods. Data from Asian and Latin American subjects with inadequate response to MTX were pooled from the APPEAL (ETN 25 mg biweekly + MTX or csDMARD + MTX; NCT00422227) and Latin RA (ETN 50 mg/week + MTX or csDMARD + MTX; NCT00848354) studies. Endpoints included the 28-joint DAS with ESR (DAS28-ESR) low disease activity (LDA; ≤3.2), DAS28 remission (<2.6) and HAQ score ≤0.5.
353. Myeloperoxidase and oxidation of uric acid in gout: implications for the clinical consequences of hyperuricaemia.
作者: Lisa K Stamp.;Rufus Turner.;Irada S Khalilova.;Mei Zhang.;Jill Drake.;Louisa V Forbes.;Anthony J Kettle.
来源: Rheumatology (Oxford). 2014年53卷11期1958-65页
The aims of this study were to establish whether, in patients with gout, MPO is released from neutrophils and urate is oxidized to allantoin and if these effects are attenuated by allopurinol.
354. Safety and efficacy of golimumab in Chinese patients with active ankylosing spondylitis: 1-year results of a multicentre, randomized, double-blind, placebo-controlled phase III trial.
作者: Chunde Bao.;Feng Huang.;Muhammad Asim Khan.;Kaiyin Fei.;Zhong Wu.;Chenglong Han.;Elizabeth C Hsia.
来源: Rheumatology (Oxford). 2014年53卷9期1654-63页
The aim of this study was to assess the efficacy and safety of golimumab in Chinese patients with active AS.
355. Clinically meaningful effect of strontium ranelate on symptoms in knee osteoarthritis: a responder analysis.
作者: Olivier Bruyère.;Jean-Yves Reginster.;Nicholas Bellamy.;Roland Chapurlat.;Pascal Richette.;Cyrus Cooper.; .
来源: Rheumatology (Oxford). 2014年53卷8期1457-64页
The aim of this study was to assess the efficacy of strontium ranelate in improving symptoms in knee OA.
356. A comparison of intense pulsed light and laser treatment of telangiectases in patients with systemic sclerosis: a within-subject randomized trial.
作者: Graham Dinsdale.;Andrea Murray.;Tonia Moore.;Janice Ferguson.;Jack Wilkinson.;Helen Richards.;Christopher E M Griffiths.;Ariane L Herrick.
来源: Rheumatology (Oxford). 2014年53卷8期1422-30页
Cutaneous telangiectases are a characteristic and psychologically distressing feature of SSc. Our aim was to assess the efficacy of two light-based treatments: pulsed dye laser (PDL) and intense pulsed light (IPL).
357. The effects of golimumab on subclinical atherosclerosis and arterial stiffness in ankylosing spondylitis—a randomized, placebo-controlled pilot trial.
作者: Lai-Shan Tam.;Qing Shang.;Emily W Kun.;Ka-Lai Lee.;Man-Lung Yip.;Martin Li.;Tena K Li.;Tracy Y Zhu.;Michelle O Pui.;Edmund K Li.;Cheuk-Man Yu.
来源: Rheumatology (Oxford). 2014年53卷6期1065-74页
Our aim was to ascertain the efficacy of golimumab compared with placebo in the prevention of atherosclerosis and arterial stiffness in AS.
358. A double-blind, randomized, placebo-controlled crossover trial of the α2C-adrenoceptor antagonist ORM-12741 for prevention of cold-induced vasospasm in patients with systemic sclerosis.
作者: Ariane L Herrick.;Andrea K Murray.;Angela Ruck.;Juha Rouru.;Tonia L Moore.;John Whiteside.;Pasi Hakulinen.;Fredrick Wigley.;Amir Snapir.
来源: Rheumatology (Oxford). 2014年53卷5期948-52页
Our primary purpose was to evaluate the efficacy of the high-potency α2C-adrenoceptor antagonist ORM-12741 in the attenuation of a cold-induced reduction in finger blood flow and temperature in patients with RP secondary to SSc. Secondary objectives were to assess safety and tolerability.
359. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events.
作者: Koshiro Sonomoto.;Kunihiro Yamaoka.;Satoshi Kubo.;Shintaro Hirata.;Shunsuke Fukuyo.;Keisuke Maeshima.;Katsunori Suzuki.;Kazuyoshi Saito.;Yoshiya Tanaka.
来源: Rheumatology (Oxford). 2014年53卷5期914-8页
To assess the effects of tofacitinib on T lymphocytes in RA patients with a special focus on efficacy and infectious adverse events (iAEs).
360. Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.
作者: Hisashi Yamanaka.;Naoki Ishiguro.;Tsutomu Takeuchi.;Nobuyuki Miyasaka.;Masaya Mukai.;Tsukasa Matsubara.;Shoji Uchida.;Hideto Akama.;Hartmut Kupper.;Vipin Arora.;Yoshiya Tanaka.
来源: Rheumatology (Oxford). 2014年53卷5期904-13页
The aim of this study was to compare efficacy outcomes of initial treatment with adalimumab + MTX vs adalimumab addition following 26 weeks of MTX monotherapy in Japanese early RA patients naive to MTX with high disease activity.
|